{"id":"NCT02297438","sponsor":"Pfizer","briefTitle":"A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]","officialTitle":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF PALBOCICLIB (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF PREVIOUSLY UNTREATED ASIAN POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) ADVANCED BREAST CANCER","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-23","primaryCompletion":"2020-08-31","completion":"2025-02-24","firstPosted":"2014-11-21","resultsPosted":"2021-11-18","lastUpdate":"2025-09-09"},"enrollment":340,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Neoplasms"],"interventions":[{"type":"DRUG","name":"Palbociclib","otherNames":["PD-0332991"]},{"type":"DRUG","name":"Letrozole","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Letrozole","otherNames":[]}],"arms":[{"label":"Palbociclib + Letrozole","type":"EXPERIMENTAL"},{"label":"Placebo + Letrozole","type":"ACTIVE_COMPARATOR"}],"summary":"The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.","primaryOutcome":{"measure":"Progression-Free Survival (PFS) Based on Investigator's Assessment","timeFrame":"Randomization up to 65 months","effectByArm":[{"arm":"Palbociclib + Letrozole","deltaMin":21.5,"sd":null},{"arm":"Placebo + Letrozole","deltaMin":13.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0012"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":5},"locations":{"siteCount":54,"countries":["China","Hong Kong","Singapore","Taiwan","Thailand"]},"refs":{"pmids":["39694573","36155117"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481027&StudyName=A%20Study%20Of%20Palbociclib%20%28PD-0332991%29%20+%20Letrozole%20VS.%20Placebo+%20Letrozole%20For%201st%20Line%20Treatment%20Of%20East%20Asian%20Postmenopausal%20Women%20Wit"]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":168},"commonTop":["Neutrophil count decreased","White blood cell count decreased","Alanine aminotransferase increased","Aspartate aminotransferase increased","Neutropenia"]}}